West Pharma Q2 net sales up 13.8%, adjusted EPS $2.37 (+28.8%); raises full-year guidance

WEST PHARMACEUTICAL SERVICES INC

Q2 net sales $872.3M (+13.8% reported, +12.7% organic); adjusted-diluted EPS $2.37 (+28.8%).
Full-year 2026 net sales guidance raised to $3.345B-$3.380B; adjusted EPS guidance raised to $8.85-$9.05.
HVP Components net sales $424.1M (+19.4%); HVP Delivery Devices $131.2M (+29.6%) driven by Biologics and GLP-1 elastomers.
Q3 2026 guidance: net sales $820M-$835M, adjusted EPS $2.14-$2.24.
Repurchased 1.8M shares for $454.3M in H1 2026; declared Q3 dividend $0.22/share.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.